Patent 9643922 was granted and assigned to Yale University on May, 2017 by the United States Patent and Trademark Office.
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.